CelliStem-OA-sEV / Cells for Cells - LARVOL DELTA

CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis (GlobeNewswire) - Cells for Cells...announced a 6-month follow-up of the groundbreaking Clinical Data from the First-ever patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San Francisco and the ISEV meeting in Lyon, France....This study reported an unprecedented WOMAC score reduction six months after a single administration of XO-101, C4C's flagship exosome therapy derived from mesenchymal stem cells (MSC)....The preclinical data gathered after 12 studies demonstrate XO-101's cartilage regeneration capacity and increased bone mineral density in cases of clinical OA in vivo....'Milestones like these are great boosters for pushing our clinical program forward. The lack of any observed adverse effect in this first-in-human trial reinforces the safety profile of C4C's MSC-derived exosomes and their potential as disease-modifying agents,'..."

P1 data • Preclinical • CNS Disorders • Osteoarthritis • Pain